Market Overview

Krystal Biotech Rallies On Positive Trial Results For Skin Condition

Share:
Krystal Biotech Rallies On Positive Trial Results For Skin Condition

Krystal Biotech Inc (NASDAQ: KRYS) shares spiked after the gene therapy company announcing positive results from its KB103 clinical trial on Monday. 

The stock was higher by 46.11% at $42.59 at the time of publication Monday. 

KB103 is Krystal’s main product that aims to treat dystrophic epidermolysis bullosa, an incurable skin blistering condition caused by a lack of collagen.

This particular gene therapy closes the majority of wounds in patients with a rare skin disorder called recessive dystrophic epidermolysis bullosa. 

“New treatments for patients suffering from EB (epidermolysis bullosa) are desperately needed, especially one that provides a convenient, painless way to administer treatment for patients suffering with this debilitating disease and to reduce their travel burden,” Dr. Peter Marinkovich, associate professor of dermatology at Stanford University and principal investigator in the GEM study, said in a statement. 

“These exciting data in the Phase 1/2 trials are supportive of this very promising new approach for treating this debilitating disease." 

Related Links:

40 Stocks Moving In Monday's Mid-Day Session 

Mid-Morning Market Update: Markets Edge Higher; Eldorado To Buy Caesars For $17.3B 

Posted-In: Biotech News General Best of Benzinga

 

Related Articles (KRYS)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Mid-Afternoon Market Update: Crude Oil Up 1%; Minerva Neurosciences Shares Spike Higher

Sustainability Spices Up McCormick & Co. Supply Chain